TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Conference call to be held Monday, November 4, 2024, at 8:30 AM ET

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

Staff

Recent Posts

EmpiRx Health Launches New Clinical Review Messaging Solution

New Text Notification Solution Strengthens the Pharmacy Care User Experience by Keeping Members Informed in…

2 hours ago

Kalorama Forecasts $2.3 Billion HbA1c Market by 2029, Driven by POC Growth, Emerging Markets, and Digital Innovation

ARLINGTON, Va., June 4, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of healthcare market…

2 hours ago

Elsevier Unveils Rigorous Evaluation Framework to Mitigate Risk in Generative AI Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open Access Journal of the…

2 hours ago

Grand Jury: City Needs to Buck Up Nonprofits and Get Out of Its Own Way to Better Help Vulnerable San Franciscans

2024–2025 San Francisco Civil Grand Jury Report calls out obstacles to effective social services grantmaking.…

2 hours ago

CIHI and GEMINI team up to modernize hospital data and improve patient care

TORONTO, June 4, 2025 /CNW/ - The Canadian Institute for Health Information (CIHI) and Unity…

2 hours ago